Flow Cytometry Clinical Development Testing

If your clinical program depends on flow cytometry data to support regulatory submissions or go/no-go decisions, the quality and consistency of that data matters more than most teams account for early on. Twenty-plus years of experience is the baseline here, not a differentiator on its own, but what that depth actually buys you is the ability to build fit-for-purpose assays aligned to your specific biology, not generic panels retrofitted to your protocol.

Eurofins Viracor BioPharma operates a globally harmonized flow cytometry network spanning North America, Europe, and Asia-Pacific, with standardized workflows covering everything from PBMC processing and cryopreservation to spectral platforms capable of high-parameter immunophenotyping and rare event detection. For cell and gene therapy programs specifically, that includes CAR-T monitoring, engineered cell tracking, receptor occupancy assays, and neutralizing antibody assessments.

Assay development and validation follow CLSI H62 guidance, and testing environments operate under CAP/CLIA, GCLP, and GLP/GLP-like frameworks. Off-the-shelf 13-color and 26-color spectral panels can accelerate study startup when timing is tight. Contact Eurofins Clinical Trial Solutions at clinicaltrials@vbp.eurofinsus.com to discuss your program requirements.